Correlation Between Biotechnology Ultrasector and Morgan Stanley

Can any of the company-specific risk be diversified away by investing in both Biotechnology Ultrasector and Morgan Stanley at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotechnology Ultrasector and Morgan Stanley into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Biotechnology Ultrasector Profund and Morgan Stanley European, you can compare the effects of market volatilities on Biotechnology Ultrasector and Morgan Stanley and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotechnology Ultrasector with a short position of Morgan Stanley. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotechnology Ultrasector and Morgan Stanley.

Diversification Opportunities for Biotechnology Ultrasector and Morgan Stanley

-0.07

Correlation Coefficient

Biotechnology Ultrasector  Morgan Stanley

Good diversification

The 3 months correlation between Biotechnology and Morgan is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Ultrasector Prof and Morgan Stanley European in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Morgan Stanley European and Biotechnology Ultrasector is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotechnology Ultrasector Profund are associated (or correlated) with Morgan Stanley. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Morgan Stanley European has no effect on the direction of Biotechnology Ultrasector i.e., Biotechnology Ultrasector and Morgan Stanley go up and down completely randomly.

Pair Corralation between Biotechnology Ultrasector and Morgan Stanley

Assuming the 90 days horizon Biotechnology Ultrasector Profund is expected to under-perform the Morgan Stanley. In addition to that, Biotechnology Ultrasector is 3.57 times more volatile than Morgan Stanley European. It trades about -0.11 of its total potential returns per unit of risk. Morgan Stanley European is currently generating about 0.38 per unit of volatility. If you would invest  2,358  in Morgan Stanley European on September 15, 2024 and sell it today you would earn a total of  140.00  from holding Morgan Stanley European or generate 5.94% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Biotechnology Ultrasector Prof  vs.  Morgan Stanley European

Biotechnology Ultrasector

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biotechnology Ultrasector Profund has generated negative risk-adjusted returns adding no value to fund investors. In spite of latest weak performance, the Fund's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the fund investors.

Morgan Stanley European

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley European are ranked lower than 5 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly strong basic indicators, Morgan Stanley is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Biotechnology Ultrasector and Morgan Stanley

The main advantage of trading using opposite Biotechnology Ultrasector and Morgan Stanley positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotechnology Ultrasector position performs unexpectedly, Morgan Stanley can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Morgan Stanley will offset losses from the drop in Morgan Stanley's long position.

The idea behind Biotechnology Ultrasector Profund and Morgan Stanley European pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.